Arrowhead Pharmaceuticals Inc. announced its fiscal 2025 second-quarter financial results, revealing a significant increase in revenue, which reached $542.7 million compared to no revenue during the same period in 2024. The company's net income attributable to Arrowhead Pharmaceuticals, Inc. was $370.4 million, contrasting sharply with a net loss of $125.3 million in the previous year. This translated to a net income per diluted share of $2.75, compared to a loss of $1.02 per share in the prior year. The company recently finalized a licensing and collaboration agreement with Sarepta Therapeutics, receiving $825 million, consisting of $500 million in cash and $325 million as an equity investment. Arrowhead is set to receive an additional $250 million over five years, and is eligible for up to $10 billion in milestone payments, as well as royalties on commercial sales. Additionally, Arrowhead announced that the FDA has accepted the New Drug Application for investigational plozasiran, aimed at treating familial chylomicronemia syndrome (FCS), a rare genetic disorder. The company is on schedule to launch plozasiran this year, pending regulatory approval.